Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

The secondary objectives of this study (Part 2) were to evaluate and compare the efficacy of the 2 treatment groups with respect to progression-free survival, overall tumor response, and duration of response, and to evaluate and compare disease control, safety, and tolerability of itacitinib in combination with docetaxel versus docetaxel alone. Part 2 of the study was not conducted.